Lonza India Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 05-07-2024
- Paid Up Capital ₹ 2.35 Cr
as on 05-07-2024
- Company Age 25 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -99.59%
(FY 2023)
- Profit -238.23%
(FY 2023)
- Ebitda -207.65%
(FY 2023)
- Net Worth -62.93%
(FY 2023)
- Total Assets -66.39%
(FY 2023)
About Lonza India
The Corporate was formerly known as Cambrex Chemicals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Abhishek Anand and Deepak Sood serve as directors at the Company.
- CIN/LLPIN
U24230HR1999PTC095355
- Company No.
117983
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 1999
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Lonza India Private Limited offer?
Lonza India Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Facilities, Pharmaceutical Capsules, Weight Loss Supplement, Slim Fit Capsules.
Who are the key members and board of directors at Lonza India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Anand  | Director | 25-Jun-2018 | Current |
| Deepak Sood | Director | 25-Jun-2018 | Current |
Financial Performance and Corporate Structure Insights of Lonza India.
Lonza India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.59% decrease. The company also saw a substantial fall in profitability, with a 238.23% decrease in profit. The company's net worth observed a substantial decline by a decrease of 62.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lonza India?
In 2023, Lonza India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Capsugel Healthcare Private LimitedActive 42 years 8 daysAbhishek Anand and Deepak Sood are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lonza India?
Lonza India has a workforce of 12 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lonza India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lonza India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
